VERTEX PHARMACEUTICALS INC / MA Quarterly Income Tax Expense (Benefit) in USD from Q1 2011 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Vertex Pharmaceuticals Inc / Ma quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2011 to Q2 2024.
  • Vertex Pharmaceuticals Inc / Ma Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $202M, a 17.7% decline year-over-year.
  • Vertex Pharmaceuticals Inc / Ma Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $705M, a 25.1% decline year-over-year.
  • Vertex Pharmaceuticals Inc / Ma annual Income Tax Expense (Benefit) for 2023 was $760M, a 16.5% decline from 2022.
  • Vertex Pharmaceuticals Inc / Ma annual Income Tax Expense (Benefit) for 2022 was $910M, a 134% increase from 2021.
  • Vertex Pharmaceuticals Inc / Ma annual Income Tax Expense (Benefit) for 2021 was $388M, a 4.17% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $705M $202M -$43.4M -17.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-02
Q1 2024 $748M $180M -$12.2M -6.36% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $760M $179M -$79.1M -30.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-15
Q3 2023 $839M $144M -$102M -41.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $941M $246M +$31.9M +14.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-02
Q1 2023 $909M $192M -$1M -0.52% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $910M $258M +$157M +156% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-15
Q3 2022 $753M $246M +$15M +6.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $738M $214M +$325M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $413M $193M +$24.9M +14.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-02
Q4 2021 $388M $101M -$184M -64.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-15
Q3 2021 $572M $231M +$152M +194% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-28
Q2 2021 $419M -$111M -$98.7M -790% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-05
Q1 2021 $518M $168M +$113M +206% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 $405M $284M +$191M +204% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-11
Q3 2020 $214M $78.4M +$65.3M +497% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $149M -$12.5M -$72.2M -121% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-30
Q1 2020 $221M $54.8M +$3.25M +6.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-30
Q4 2019 $218M $93.7M +$1.59B Oct 1, 2019 Dec 31, 2019 10-K 2021-02-11
Q3 2019 -$1.37B $13.1M +$5.09M +63.2% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-11
Q2 2019 -$1.37B $59.7M +$49.4M +477% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-11
Q1 2019 -$1.42B $51.5M +$64.2M Jan 1, 2019 Mar 31, 2019 10-K 2021-02-11
Q4 2018 -$1.49B -$1.49B -$1.5B -14652% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-13
Q3 2018 $16M $8.06M +$134M Jul 1, 2018 Sep 30, 2018 10-K 2020-02-13
Q2 2018 -$118M $10.3M +$6M +138% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-13
Q1 2018 -$124M -$12.7M -$16.6M -418% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-13
Q4 2017 -$107M $10.3M +$17.7M Oct 1, 2017 Dec 31, 2017 10-K 2019-02-13
Q3 2017 -$125M -$126M -$126M -25130% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-13
Q2 2017 $1.37M $4.34M -$13.8M -76.1% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-13
Q1 2017 $15.2M $3.99M -$1.5M -27.3% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-13
Q4 2016 $16.7M -$7.45M -$6.07M -440% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-15
Q3 2016 $22.7M $503K -$827K -62.2% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-15
Q2 2016 $23.6M $18.1M -$12M -39.8% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-15
Q1 2016 $35.6M $5.49M +$5.19M +1734% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-15
Q4 2015 $30.4M -$1.38M -$3.42M -167% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-23
Q3 2015 $33.8M $1.33M -$2.09M -61.1% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-23
Q2 2015 $35.9M $30.1M +$29.4M +4248% Apr 1, 2015 Jun 30, 2015 10-K 2017-02-23
Q1 2015 $6.45M $299K -$504K -62.8% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-23
Q4 2014 $6.96M $2.04M +$691K +51.1% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-16
Q3 2014 $6.27M $3.42M +$864K +33.8% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-16
Q2 2014 $5.4M $693K +$135K +24.2% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-16
Q1 2014 $5.27M $803K +$128M Jan 1, 2014 Mar 31, 2014 10-K 2016-02-16
Q4 2013 -$122M $1.35M +$4.05M Oct 1, 2013 Dec 31, 2013 10-K 2015-02-13
Q3 2013 -$126M $2.56M -$18.8M -88% Jul 1, 2013 Sep 30, 2013 10-K 2015-02-13
Q2 2013 -$108M $558K -$19.5M -97.2% Apr 1, 2013 Jun 30, 2013 10-K 2015-02-13
Q1 2013 -$88.2M -$127M -$127M Jan 1, 2013 Mar 31, 2013 10-K 2015-02-13
Q4 2012 $38.8M -$2.7M -$25.4M -112% Oct 1, 2012 Dec 31, 2012 10-K 2014-02-11
Q3 2012 $64.1M $21.4M +$49.2M Jul 1, 2012 Sep 30, 2012 10-K 2014-02-11
Q2 2012 $14.9M $20.1M -$4.39M -17.9% Apr 1, 2012 Jun 30, 2012 10-K 2014-02-11
Q1 2012 $19.3M $32K* +$32K Jan 1, 2012 Mar 31, 2012 10-K 2014-02-11
Q4 2011 $19.3M $22.7M Oct 1, 2011 Dec 31, 2011 10-K 2013-03-01
Q3 2011 -$27.8M Jul 1, 2011 Sep 30, 2011 10-K 2013-03-01
Q2 2011 $24.4M Apr 1, 2011 Jun 30, 2011 10-K 2013-03-01
Q1 2011 $0 Jan 1, 2011 Mar 31, 2011 10-K 2013-03-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.